Antiplatelet therapy - Aspirin, ticlopidine/clopidogrel, and anti-integrin agents

被引：9

作者：

Calverley, DC

Roth, GJ

机构：

[1] Univ So Calif, Div Hematol, Los Angeles, CA 90033 USA

[2] Univ Washington, Div Hematol, Seattle, WA 98195 USA

[3] Vet Affairs Puget Sound Hlth Care Syst, Hematol Sect, Seattle, WA USA

来源：

HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA | 1998年 / 12卷 / 06期

关键词：

D O I：

10.1016/S0889-8588(05)70051-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.

引用

页码：1231 / +

页数：20

共 123 条

[1] ATRIAL-FIBRILLATION AND STROKE - 3 NEW STUDIES, 3 REMAINING QUESTIONS [J].

ALBERS, GW .

ARCHIVES OF INTERNAL MEDICINE, 1994, 154 (13) :1443-1448

[2] COLLABORATIVE OVERVIEW OF RANDOMIZED TRIALS OF ANTIPLATELET THERAPY .1. PREVENTION OF DEATH, MYOCARDIAL-INFARCTION, AND STROKE BY PROLONGED ANTIPLATELET THERAPY IN VARIOUS CATEGORIES OF PATIENTS [J].

ALTMAN, R ;

CARRERAS, L ;

DIAZ, R ;

FIGUEROA, E ;

PAOLASSO, E ;

PARODI, JC ;

CADE, JF ;

DONNAN, G ;

EADIE, MJ ;

GAVAGHAN, TP ;

OSULLIVAN, EF ;

PARKIN, D ;

RENNY, JTG ;

SILAGY, C ;

VINAZZER, H ;

ZEKERT, F ;

ADRIAENSEN, H ;

BERTRANDHARDY, JM ;

BRAN, M ;

DAVID, JL ;

DRICOT, J ;

LAVENNEPARDONGE, E ;

LIMET, R ;

LOWENTHAL, A ;

MORIAU, M ;

SCHAPIRA, S ;

SMETS, P ;

SYMOENS, J ;

VERHAEGHE, R ;

VERSTRAETE, M ;

ATALLAH, A ;

BARNETT, H ;

BATISTA, R ;

BLAKELY, J ;

CAIRNS, JA ;

COTE, R ;

CROUCH, J ;

EVANS, G ;

FINDLAY, JM ;

GENT, M ;

LANGLOIS, Y ;

LECLERC, J ;

NORRIS, J ;

PINEO, GF ;

POWERS, PJ ;

ROBERTS, R ;

SCHWARTZ, L ;

SICURELLA, J ;

TAYLOR, W ;

THEROUX, P .

BMJ-BRITISH MEDICAL JOURNAL, 1994, 308 (6921) :81-100

[3]

[Anonymous], 1988, BRIT MED J, V296, P320

[4]

[Anonymous], 1991, Lancet, V338, P1345

[5] MULTICENTER DOUBLE-BLIND-STUDY OF TICLOPIDINE IN THE TREATMENT OF INTERMITTENT CLAUDICATION AND THE PREVENTION OF ITS COMPLICATIONS [J].

ARCAN, JC ;

BLANCHARD, J ;

BOISSEL, JP ;

DESTORS, JM ;

PANAK, E .

ANGIOLOGY, 1988, 39 (09) :802-811

[6] PROTEIN-KINASE-C, CALCIUM AND PHOSPHOLIPID DEGRADATION [J].

ASAOKA, Y ;

NAKAMURA, S ;

YOSHIDA, K ;

NISHIZUKA, Y .

TRENDS IN BIOCHEMICAL SCIENCES, 1992, 17 (10) :414-417

[7] ANTIPLATELET TREATMENT WITH TICLOPIDINE IN UNSTABLE ANGINA - A CONTROLLED MULTICENTER CLINICAL-TRIAL [J].

BALSANO, F ;

RIZZON, P ;

VIOLI, F ;

SCRUTINIO, D ;

CIMMINIELLO, C ;

AGUGLIA, F ;

PASOTTI, C ;

RUDELLI, G .

CIRCULATION, 1990, 82 (01) :17-26

[8]

BALSANO F, 1989, J LAB CLIN MED, V114, P84

[9] Aspirin dose in stroke prevention - Beautiful hypotheses slain by ugly facts [J].

Barnett, HJM ;

Kaste, M ;

Meldrum, H ;

Eliasziw, M .

STROKE, 1996, 27 (04) :588-592

[10] DRUG-THERAPY - DRUGS AND SURGERY IN THE PREVENTION OF ISCHEMIC STROKE [J].

BARNETT, HJM ;

ELIASZIW, M ;

MELDRUM, HE .

NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (04) :238-248

← 1 2 3 4 5 6 7 8 9 10 →